لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: De Silva MK; From the Department of Medical Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia., Chan DLH, Bernard EJ, Conner AJ; From the Department of Medical Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia., Mascall SL; From the Department of Medical Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia., Bailey DL, Roach PJ, Clarke SJ, Diakos CI, Pavlakis N, Schembri G

المصدر: Pancreas [Pancreas] 2024 Aug 01; Vol. 53 (7), pp. e560-e565.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 8608542 Publication Model: Print Cited Medium: Internet ISSN: 1536-4828 (Electronic) Linking ISSN: 08853177 NLM ISO Abbreviation: Pancreas Subsets: MEDLINE

مواضيع طبية MeSH: Neuroendocrine Tumors*/pathology , Neuroendocrine Tumors*/radiotherapy , Neuroendocrine Tumors*/diagnostic imaging , Neuroendocrine Tumors*/metabolism , Neuroendocrine Tumors*/mortality , Fluorodeoxyglucose F18* , Octreotide*/analogs & derivatives , Octreotide*/therapeutic use , Radiopharmaceuticals* , Positron-Emission Tomography*/methods , Tumor Burden* , Organometallic Compounds*/therapeutic use, Humans ; Male ; Middle Aged ; Female ; Retrospective Studies ; Aged ; Prognosis ; Adult ; Receptors, Peptide/metabolism ; Glycolysis ; Aged, 80 and over ; Pancreatic Neoplasms/pathology ; Pancreatic Neoplasms/radiotherapy ; Pancreatic Neoplasms/diagnostic imaging ; Pancreatic Neoplasms/mortality ; Progression-Free Survival ; Treatment Outcome

المؤلفون: De Silva M; Bowel Cancer and Biomarker Research Laboratory, Kolling Institute, Royal North Shore Hospital, St Leonards, NSW, Australia.; Department of Medical Oncology, Royal North Shore Hospital, St. Leonards, NSW, Australia., Tse BCY; Bowel Cancer and Biomarker Research Laboratory, Kolling Institute, Royal North Shore Hospital, St Leonards, NSW, Australia., Diakos CI; Department of Medical Oncology, Royal North Shore Hospital, St. Leonards, NSW, Australia.; Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia., Clarke S; Department of Medical Oncology, Royal North Shore Hospital, St. Leonards, NSW, Australia.; Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia., Molloy MP; Bowel Cancer and Biomarker Research Laboratory, Kolling Institute, Royal North Shore Hospital, St Leonards, NSW, Australia. m.molloy@sydney.edu.au.; Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia. m.molloy@sydney.edu.au.

المصدر: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2024 Feb 14; Vol. 73 (3), pp. 53. Date of Electronic Publication: 2024 Feb 14.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE

مواضيع طبية MeSH: Immunogenic Cell Death* , Colorectal Neoplasms*/drug therapy, Humans ; Immunosuppressive Agents ; Tumor Microenvironment

المؤلفون: Batty K; Medical Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia., Taylor AM; Medical Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia., Bernard EJ; Nuclear Medicine, Royal North Shore Hospital, Sydney, New South Wales, Australia., Diakos CI; Medical Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia.; Bill Walsh Translational Cancer Research Laboratory, Kolling Institute, University of Sydney, Sydney, New South Wales, Australia., Clarke SJ; Medical Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia.; Bill Walsh Translational Cancer Research Laboratory, Kolling Institute, University of Sydney, Sydney, New South Wales, Australia., Guminski A; Medical Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia., Baron-Hay S; Medical Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia., Boyle F; Patricia Ritchie Centre for Breast Cancer Research, Mater Hospital, North Sydney and University of Sydney, The Mater Hospital, Sydney, New South Wales, Australia.; University of Sydney, Sydney, Australia., Pavlakis N; Medical Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia.; Bill Walsh Translational Cancer Research Laboratory, Kolling Institute, University of Sydney, Sydney, New South Wales, Australia., Chan DL; Medical Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia.; Bill Walsh Translational Cancer Research Laboratory, Kolling Institute, University of Sydney, Sydney, New South Wales, Australia.

المصدر: Internal medicine journal [Intern Med J] 2023 Oct; Vol. 53 (10), pp. 1813-1818. Date of Electronic Publication: 2022 Oct 31.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Blackwell Science Asia Country of Publication: Australia NLM ID: 101092952 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1445-5994 (Electronic) Linking ISSN: 14440903 NLM ISO Abbreviation: Intern Med J Subsets: MEDLINE

مواضيع طبية MeSH: Neuroendocrine Tumors*/diagnostic imaging , Neuroendocrine Tumors*/therapy , Breast Neoplasms*/diagnostic imaging , Breast Neoplasms*/therapy , Carcinoma, Neuroendocrine*/diagnostic imaging , Carcinoma, Neuroendocrine*/therapy , Neoplasms, Second Primary*, Humans ; Female ; Adult ; Middle Aged ; Prognosis ; Fluorodeoxyglucose F18 ; Retrospective Studies